Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O75914

UPID:
PAK3_HUMAN

ALTERNATIVE NAMES:
Beta-PAK; Oligophrenin-3; p21-activated kinase 3

ALTERNATIVE UPACC:
O75914; A8K389; B1GX77; B1GX78; B1GX79; Q5JWX1; Q5JWX2; Q7Z2D6; Q7Z2E4; Q7Z3Z8; Q8WWK5; Q8WX23; Q9P0J8

BACKGROUND:
The Serine/threonine-protein kinase PAK 3, known alternatively as Beta-PAK, Oligophrenin-3, and p21-activated kinase 3, plays a crucial role in signaling pathways related to cytoskeleton regulation, cell migration, and cell cycle regulation. It acts downstream of CDC42 and RAC1, contributing to dendritic spine and synapse formation. Its kinase activity is vital for phosphorylating targets like MAPK4 and MAPK6, leading to the activation of MAPKAPK5 and modulation of cell migration and neuronal development.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Intellectual developmental disorder, X-linked 30, Serine/threonine-protein kinase PAK 3 represents a promising target for drug discovery. Understanding its function could pave the way for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.